Physicians' Academy for Cardiovascular Education

Anacetrapib & HDL-C: Hope for CETP Inhibitors?

Literature - Ronen Gurfinkel & Tisha R. Joy

Anacetrapib: Hope for CETP Inhibitors?

REVIEW

Ronen Gurfinkel & Tisha R. Joy,  Cardiovascular Therapeutics 29 (2011) 327–339


Summary
 

Inhibition of cholesteryl ester transfer protein (CETP), a key protein involved in reverse cholesterol transport, can lead to increases in high-density lipoprotein cholesterol (HDL-C) levels and thus, is under evaluation as an antiatherogenic strategy. Several CETP inhibitors have been under development including anacetrapib, dalcetrapib, and torcetrapib. To date, anacetrapib demonstrates the greatest HDL-C raising and low-density lipoprotein cholesterol (LDL-C) lowering potential. Phase I and phase II trials with anacetrapib have revealed that anacetrapib is well-tolerated and does not seem to possess the pressor effects associated with torcetrapib. This article will briefly review the HDL-C raising through CETP inhibition as an antiatherogenic strategy with a specific focus on anacetrapib.


Background

Despite advances in the management of blood lipid abnormalities using statins, a high incidence of cardiovascular morbidity and mortality still remains (1). The inverse relationship between HDL-C levels and cardiovascular risk has initiated pharmacologic efforts to raise HDL-C to lower cardiovascular risk (2). CETP is a glycoprotein , which circulates largely bound to HDL (3). CETP levels may be 70-80% higher in people with hyperlipidemia. Inhibitors of cholesteryl ester transfer protein (CETP) that have been shown to raise HDL-C have been under development and include torcetrapib, dalcetrapib and anacetrapib.


CETP inhibition and anacetrapib

From the mentioned CETP inhibitors, the development of torcetrapib has been seized due to adverse clinical outcomes, which are thought to be caused by the induction of both cortisole and aldosterone. Newer drugs such as anacetrapib are understandably evaluated on their effect on safety.

Compared to torcetrapib or dalcetrapib, anacetrapib seems to be a potent CETP inhibitor with regard to both HDL-C raising and LDL-C lowering capability. Preclinical data did not indicate that anacetrapib shares the adverse off target effects seen with torcetrapib (4). Clinical data has shown that both dalcetrapib and anacetrapib do not increase blood pressure, as seen with torcetrapib. Anacetrapib seems to be well tolerated (5,6,7).

Direct evidence however of an antiatherogenic effect of CETP inhibition, and the impact of CETP inhibition on reverse cholesterol transport and on atherogenesis has yet to be delivered. Moreover, completion of long-term phase III studies with populations at risk for CVD events is underway to establish the clinical significance of anacetrapib through its modification of the lipid profile. The effect on HDL increase must also been evaluated in tems of HDL functionality and HDL particles and ultimately hard cardiovascular endpoints.



Conclusions

The HDL raising capacity demonstrated by anacetrapib has been clearly demonstrated. Adverse effects, especially the pressor effects seen with torcetrapib have not been reproduced in anacetrapib trials. Results of clinical trials are underway to assess the effect of anacetrapib in hard cardiovascular outcomes.


Reverse cholesterol transport CETP is key in remodeling of HDL
CETP activity Potential pro- and antiatherogenic effects

References


1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707–714.
3. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255–1274.`
4. Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009;150:2211–2219.
5. Hermann F, Enseleit F, Spieker LE, et al. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thrombosis Res 2009;123:460–465.
6. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907–1914.
7. O’Neill E, Sparrow CP, Chen Y, et al. Identification and characterization of MK-0859, a novel cholesteryl ester transfer protein inhibitor. J Clin Lipidol 2007;1:367.

Share this page with your colleagues and friends: